These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 25884169)
1. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169 [TBL] [Abstract][Full Text] [Related]
2. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584 [TBL] [Abstract][Full Text] [Related]
4. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?]. Schnabel PA; Junker K Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813 [TBL] [Abstract][Full Text] [Related]
5. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194 [TBL] [Abstract][Full Text] [Related]
6. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors. Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920 [TBL] [Abstract][Full Text] [Related]
8. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes. Lázaro S; Pérez-Crespo M; Lorz C; Bernardini A; Oteo M; Enguita AB; Romero E; Hernández P; Tomás L; Morcillo MÁ; Paramio JM; Santos M Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22300-22306. PubMed ID: 31611390 [TBL] [Abstract][Full Text] [Related]
9. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922 [TBL] [Abstract][Full Text] [Related]
10. Molecular markers help characterize neuroendocrine lung tumors. Rusch VW; Klimstra DS; Venkatraman ES Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011 [TBL] [Abstract][Full Text] [Related]
11. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652 [TBL] [Abstract][Full Text] [Related]
12. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses. Yeh YC; Chou TY J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337 [TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Swarts DR; Ramaekers FC; Speel EJ Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738 [TBL] [Abstract][Full Text] [Related]
14. Comparative proteomics of pulmonary tumors with neuroendocrine differentiation. Cho NH; Koh ES; Lee DW; Kim H; Choi YP; Cho SH; Kim DS J Proteome Res; 2006 Mar; 5(3):643-50. PubMed ID: 16512680 [TBL] [Abstract][Full Text] [Related]
15. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid. Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M J BUON; 2019; 24(1):256-266. PubMed ID: 30941978 [TBL] [Abstract][Full Text] [Related]
16. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Pelosi G; Pasini F; Fraggetta F; Pastorino U; Iannucci A; Maisonneuve P; Arrigoni G; De Manzoni G; Bresaola E; Viale G Lung Cancer; 2003 Nov; 42(2):203-13. PubMed ID: 14568688 [TBL] [Abstract][Full Text] [Related]
17. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors]. Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557 [TBL] [Abstract][Full Text] [Related]
18. Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Portela-Gomes GM; Grimelius L; Stridsberg M; Bresaola E; Viale G; Pelosi G Virchows Arch; 2005 Jun; 446(6):604-12. PubMed ID: 15906087 [TBL] [Abstract][Full Text] [Related]
19. Co-expression of TTF-1 and neuroendocrine markers in the human fetal lung and pulmonary neuroendocrine tumors. Miskovic J; Brekalo Z; Vukojevic K; Miskovic HR; Kraljevic D; Todorovic J; Soljic V Acta Histochem; 2015; 117(4-5):451-9. PubMed ID: 25722034 [TBL] [Abstract][Full Text] [Related]
20. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]